Global pharma giant AstraZeneca’s Phase III LATIFY trial testing ceralasertib in combination with Imfinzi (durvalumab) has missed its primary goal of improving overall survival compared with standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 

 

The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy.

 

“Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped responding to available therapies by combining ATR inhibition with immunotherapy. 

 

"While we are disappointed by this result, we remain committed to pioneering new medicines to address the urgent need to improve outcomes for patients with lung cancer through our industry-leading portfolio,” said Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca.

 

Despite the setback, the combination therapy was generally well tolerated, with a safety profile consistent with the known effects of each individual drug and no new safety concerns identified. AstraZeneca plans to present the full data at an upcoming medical meeting.